Patient Centricity
Grifols works to maintain trusted relationships with patient organizations, which are a critical voice for their members. We support these groups with reliable and transparent information in their efforts to increase disease awareness, promote early diagnosis, provide education and support, and advocate for improved availability of treatment and care.
Safety and quality as priority requirements
Grifols is committed to building a sustainable and responsible value chain that goes beyond strict regulatory requirements for quality, safety and sustainability. By ensuring the safety and quality of its treatments, the company reaffirms its commitment to prioritize the needs of patients, healthcare professionals and customers.
390+
quality control supplier audits performed in 2024
800,000+
patients treated
$29,825M
positive impact on patients
ADVOCATE
Grifols serves as a reliable source of information for patient communities and policymakers. We work to better understand the needs of our patients and advocate alongside them in an effort to overcome healthcare barriers.
EDUCATE
Grifols routinely hosts on-site and virtual educational events to provide patients with a deeper understanding of the journey of plasma from donor to patient, including tours of our plasma collection and manufacturing sites.
SUPPORT
Grifols believes in supporting the missions of our patient advocacy organization partners by providing charitable donations that help maintain the independence of these organizations while promoting sustainable operations.
ENGAGE
Grifols connects patient communities with plasma donors and employees to share their patient journey. We also partner with patient communities and patient organizations through ongoing collaborations on priority projects including awareness, early diagnosis and access to care.
Engagement initiatives are governed by a global policy for patient and patient organizations, which can be read here.
At Grifols, patient centricity is an ethos that is both aspirational and the foundation of a purpose-driven approach to achieving our mission.
Improving access to treatment
Blood plasma contains hundreds of essential proteins and antibodies vital to the body's ability to maintain critical functions. Thanks to the generosity of plasma donors, Grifols is able to produce plasma-derived medicines that treat chronic, rare, prevalent and, at times, life-threatening conditions.
The patients we serve around the world can lead better lives thanks to donors and the plasma-derived medicines they make possible. Patients drive the work we do every day.
Humanitarian aid initiatives
As a global healthcare company, Grifols recognizes its responsibility in providing humanitarian aid and emergency support. We work with Direct Relief to provide healthcare practitioners with medical resources following natural disasters and other humanitarian emergencies. The majority of requests are for our specific immunoglobulin products that provide protection following viral or bacterial exposure.
Since 2014, Grifols has partnered with the World Federation of Hemophilia's Humanitarian Assistance Program to provide clotting factor therapies globally. In 2021, we extended our commitment to this program by committing to providing an additional 240M international units (IU) of clotting factor by 2030.
17,000+
patients with access to free products or services
€18.6M
in product donations
Awards to improve care of patients with hemophilia
To support patients with hemophilia in countries with limited economic resources, Grifols in 2019 created the Grifols Hemophilia Awareness Global Awards (GHAGA). The program’s two editions encouraged healthcare providers, hemophilia treatment centers as well as hemophilia societies to drive initiatives that contributed to improving care for hemophilia patients and enhancing their quality of life.
Patient Stories
We work to better understand the patient journey, including the challenges patients face and what it means to live with chronic diseases. The company communicates these experiences across our organization to guide daily decision-making and continue innovating to improve the quality of life of patients.
“My diagnosis took a long time, around 25 years. My situation prior to the diagnosis had been difficult because I spent a lot of time at hospitals, and I was uncertain because I never knew when I wouldn't be able to breathe.”
“I think that we would not be here today without plasma donors. And their donation is very, very important and it is a big part of what we have today. Our health depends on their donations, and I will be forever grateful.”
“Going from not being able to live a normal life, makes normal life much more enjoyable than it would have been otherwise. So, I enjoy things a little bit more because I didn’t always have them.”
“If somebody were recently diagnosed or had a child recently diagnosed, I would say reach out and get support. The immune deficiency community is strong and there’s always somebody who’s willing to answer questions, share ideas.”
Chronic diseases treated with plasma therapies and other innovative solutions
Learn more
Supporting donors
Grifols' commitment to donors entails safeguarding their health and safety and generating positive social and economic value in the communities where they live.
Scientific Awards and Programs
We support the scientific community and its work to improve therapeutic options for patients through scientific awards, scholarships, research-sponsored programs, and a peer-reviewed journal.
Transparency disclosures
Our interactions with the patient community are disclosed in full detail.
Impact on Society
Caring for people
Grifols, we are people helping people. Each of us contributes to fulfill our mission of improving people's health and well-being.